Redcliffe Labs key facts
as of Oct 2026- Operator of a diagnostics and precision medicine company intended to offer reproductive health testing, rare diseases, and cancer gene diagnosis for patients.
- Redcliffe Labs is valued at approximately $491.0M as of Oct 2026 (last reported valuation).
- It has raised $122.5M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Y Combinator, Astir Ventures, Rebel Fund, Sprint VC, Kube VC — 35 tracked in total.
- Status: Privately Held (backing).
Redcliffe Labs's last reported valuation, Sep 2024. Nothing priced has surfaced since.
- ·The complete investor list: 35 names
- ·Watch Redcliffe Labs: the Monday email on marks, rounds and moves
Redcliffe Labs funding rounds
No funding rounds for Redcliffe Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Redcliffe Labs
35+Membership and data by Private Market View
Redcliffe Labs valuation
Redcliffe Labs's last reported valuation was $491 million in Sep 2024. No priced round, secondary trade or fund mark has surfaced since.
Redcliffe Labs investors
35 investors are on record for Redcliffe Labs, including Y Combinator, Astir Ventures, Rebel Fund and Sprint VC. By type, the record holds 6 venture capital firms.
About Redcliffe Labs
Operator of a diagnostics and precision medicine company intended to offer reproductive health testing, rare diseases, and cancer gene diagnosis for patients. The company uses in-house technology to offer various screening services combined with regular counseling and clinical data management, and also provides comprehensive testing of cancer and genetic disorders, enabling patients to avail of diagnosis in all relevant aspects of pregnancy, health, and fertility care.
- Sector
- Healthcare
- HQ
- Noida, India
- Founded
- 2018
- Employees
- 1,858
- Website
- redcliffelabs.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.